MRD and Relapse in Patients With AML

Drs Gail Roboz and Roland Walter discuss measurable residual disease and relapse in patients with acute myeloid leukemia.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/964539). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

Bone Marrow Biopsy https://emedicine.medscape.com/article/197802-workup

Stem Cell Transplant https://emedicine.medscape.com/article/208954-overview

Donor Lymphocyte Infusions https://pubmed.ncbi.nlm.nih.gov/11941577/

Hypomethylating Agents https://emedicine.medscape.com/article/197802-treatment

FLT3, IDH2 https://emedicine.medscape.com/article/197802-workup#c9

Measurable Residual Disease https://decisionpoint.medscape.com/oncology/viewarticle/928279

2021 Update on MRD in Acute Myeloid Leukemia: A Consensus Document From the European LeukemiaNet MRD Working Party https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718623/

Measurable Residual Disease as a Biomarker in Acute Myeloid Leukemia: Theoretical and Practical Considerations https://www.nature.com/articles/s41375-021-01230-4

Core Binding Factor https://www.medscape.com/viewarticle/408452_4

Minimal Residual Disease Eradication With Epigenetic Therapy in Core Binding Factor Acute Myeloid Leukemia https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779853/

Minimal Residual Disease Monitoring by Quantitative RT-PCR in Core Binding Factor AML Allows Risk Stratification and Predicts Relapse: Results of the United Kingdom MRC AML-15 Trial https://ashpublications.org/blood/article/120/14/2826/30510/Minimal-residual-disease-monitoring-by

MRD-Directed Risk Stratification Treatment May Improve Outcomes of t(8;21) AML in the First Complete Remission: Results From the AML05 Multicenter Trial https://pubmed.ncbi.nlm.nih.gov/23535063/